Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, discusses cost-saving implications of biosimilars in oncology, as well as several barriers that continue to impede their use.
Kathy Oubre, MS, is the chief operating officer of Pontchartrain Cancer Center.
Transcript
There are several challenges to biosimilar integration in cancer care, particularly intervention from payers in allowing access to providers. How has this issue fared in recent years and what other barriers persist?
Payers continue to insert their influence in the physician-patient relationship by step edits and formulary restrictions. For example, biosimilars are often not preferred over reference products by the majority of US health care plans.
In addition, biosimilars are also not even on the formulary of most of our state Medicaids, and physician preference has been slow to adoption. A 2019 survey found that the majority of oncology products still are not used with biosimilars or they're used only in supportive care or some physicians prefer not to switch patients during a launch.
On a bright note, though, the recent Bernstein analysis that I mentioned earlier shows that these attitudes are changing. And even with the most modest uptake and challenges around biosimilar adoption, a recent IQVIA report shows that biosimilar-related savings will range from $49 to $140 billion over the next 5 years.
How has the pandemic impacted biosimilar adoption in cancer care delivery?
I think that answer has 2 parts. Similar to most drug launches during COVID-19, it's just been really difficult to keep up with new biosimilar drug launches during this time due to lack of access with our pharma partners.
However, as many people continue to have their hours cut or lose their jobs and just be faced with financial insecurities during this time, the cost savings of biosimilars have helped many people be able to continue and afford their treatments.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More